ijms-logo

Journal Browser

Journal Browser

Challenges and Future Trends of Inflammatory Skin Diseases Treatment, 2nd Ediion

A special issue of International Journal of Molecular Sciences (ISSN 1422-0067). This special issue belongs to the section "Molecular Pathology, Diagnostics, and Therapeutics".

Deadline for manuscript submissions: closed (30 October 2024) | Viewed by 1967

Special Issue Editor

Department of Dermatology, Yeouido St. Mary’s Hospital, College of Medicine, The Catholic University of Korea, Seoul 07345, Republic of Korea
Interests: anticancer drug
Special Issues, Collections and Topics in MDPI journals

Special Issue Information

Dear Colleagues,

Inflammatory skin diseases, such as psoriasis, atopic dermatitis, hidradenitis suppurativa, and acne, are among the most challenging conditions treated by dermatologists worldwide. With the increasing prevalence and chronic nature of these conditions, the demand for innovative and effective therapies is growing rapidly. Over the years, numerous treatments, such as biologics, have been introduced that offer hope for those suffering from inflammatory skin disease. The introduction of biologics has revolutionized the treatment of inflammatory skin diseases. They offer a targeted approach to treating these conditions with minimal side effects compared to traditional systemic treatments, such as steroids or methotrexate; thus, this Special Issue on “Challenges and Future Trends of Inflammatory Skin Diseases Treatment, 2nd Ediion” aims to highlight the current challenges faced in treating these disorders and explore potential future trends that could greatly impact patient care.

As volume 1 of the Special Issue “Challenges and Future Trends of Inflammatory Skin Diseases Treatment” has been successful, we will be exploring this issue further in the International Journal of Molecular Sciences (ISSN: 1422-0067, IF: 5.923, JCR Category Q1). This second Special Issue provides a summary of those emerging fields, with an emphasis on novel developments in the treatment modalities of inflammatory skin diseases and novel findings on the pathogenesis of diseases targeted by these therapies. We welcome articles covering promising developments and future trends, such as a better understanding of pathogenesis, personalized treatments, and digital health technologies. Through this feature, we hope to foster collaborative efforts and inspire new approaches to improve the lives of patients with inflammatory skin diseases.

https://www.mdpi.com/journal/ijms/special_issues/75IV7LO61S

Dr. Miri Kim
Guest Editor

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. International Journal of Molecular Sciences is an international peer-reviewed open access semimonthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. There is an Article Processing Charge (APC) for publication in this open access journal. For details about the APC please see here. Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

Keywords

  • inflammatory skin disease
  • psoriasis
  • atopic dermatitis
  • biologics
  • future trends

Benefits of Publishing in a Special Issue

  • Ease of navigation: Grouping papers by topic helps scholars navigate broad scope journals more efficiently.
  • Greater discoverability: Special Issues support the reach and impact of scientific research. Articles in Special Issues are more discoverable and cited more frequently.
  • Expansion of research network: Special Issues facilitate connections among authors, fostering scientific collaborations.
  • External promotion: Articles in Special Issues are often promoted through the journal's social media, increasing their visibility.
  • e-Book format: Special Issues with more than 10 articles can be published as dedicated e-books, ensuring wide and rapid dissemination.

Further information on MDPI's Special Issue policies can be found here.

Published Papers (1 paper)

Order results
Result details
Select all
Export citation of selected articles as:

Research

14 pages, 3697 KiB  
Article
Efficacy and Potential Mechanisms of Naringin in Atopic Dermatitis
by Seung-Ah Yoo, Ki-Chan Kim and Ji-Hyun Lee
Int. J. Mol. Sci. 2024, 25(20), 11064; https://doi.org/10.3390/ijms252011064 - 15 Oct 2024
Cited by 2 | Viewed by 1695
Abstract
Atopic dermatitis (AD) is one of the most prevalent chronic inflammatory skin diseases. Topical treatments are recommended for all patients regardless of severity, making it essential to develop an effective topical AD treatment with minimal side effects; We investigated the efficacy of topical [...] Read more.
Atopic dermatitis (AD) is one of the most prevalent chronic inflammatory skin diseases. Topical treatments are recommended for all patients regardless of severity, making it essential to develop an effective topical AD treatment with minimal side effects; We investigated the efficacy of topical application of naringin in AD and explored the possible mechanisms using an AD mouse model induced by 1-chloro-2,4-dinitrobenzene (DNCB). Clinical, histological, and immunological changes related to AD and Janus kinase (JAK)-signal transducer and activator of transcription (STAT) signaling proteins in the skin tissues were measured as outcomes; Naringin treatment resulted in a significant improvement in dermatitis severity score and reduced epidermal thickness and mast cell count in the skin (p < 0.05). Naringin also demonstrated the ability to inhibit DNCB-induced changes in interleukin (IL) 4, chemokine (C-C motif) ligand (CCL) 17, CCL22, IL1β, interferon-gamma (IFN-γ), and tumor necrosis factor-alpha (TNF-α) levels by quantitative real-time polymerase chain reaction (qRT-PCR) and IL13 by enzyme-linked immunosorbent assay (ELISA) (p < 0.05). Western blot results exhibited the decreased JAK1, JAK2, STAT1, STAT3, phospho-STAT3, and STAT6 expression in the naringin-treated groups (p < 0.05); The findings of this study suggest that topical naringin may effectively improve the symptoms of AD and could be used as a therapeutic agent for AD. Full article
Show Figures

Figure 1

Back to TopTop